来源：上海证券报·中国证券网 公司表示，报告期公司营业收入为确认的技术授权和技术合作收入。另外，格索雷塞注册临床试验于 2024年结束，报告期内与其相关的研发投入相应减少，致使前三个季度研发投入同比减少35.86%。 （高毅） 上证报中国证券网讯 益方生物10月29日晚发布第三季度报告，本报告期，公司实现营业收入1173万 元，同比大增173.86%，公司前三季度实现营业收入3089万元，同比增长61.27%。报告期内公司实现归 母净利润亏损6181万元，去年同期亏损9109万元，同比减亏2928万元，年初至报告期末归母净利润亏损 1.81亿元，同比减亏1.24亿元。 ...

Core Insights - The company reported a revenue of 149,742,032.70 yuan for the first three quarters of 2025, representing a year-on-year decline of 14.15% [2] - The net profit attributable to shareholders of the listed company was 20,329,681.80 yuan, showing a slight year-on-year increase of 0.77% [2] Financial Performance - Revenue for the first three quarters of 2025: 149.74 million yuan, down 14.15% year-on-year [2] - Net profit for the same period: 20.33 million yuan, up 0.77% year-on-year [2]

每经AI快讯，科兴制药（SH 688136，收盘价：38.1元）10月29日晚间发布三季度业绩公告称，2025年 前三季度营收约11.48亿元，同比增加10.54%；归属于上市公司股东的净利润约1.11亿元，同比增加 547.7%；基本每股收益0.56元，同比增加522.22%。 截至发稿，科兴制药市值为77亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 王晓波） ...

市也上了，但农业部非 转基因 种植安全证书到底要不要？400亿市值的公众公司 禾元生物 要给个说法！ 一边是科创板上市首日股价飙升202%的资本宠儿，一边是农业农村部口中需要但尚未取得的转基因安全证书，禾元生物的稻米造血神话背后，藏 着多少欲说还休的故事？ 10月28日，武汉禾元生物科技股份有限公司成功登陆科创板，成为科 创成长 层首批新注册公司之一，上市首日股价大幅上涨约202%，开盘价达 88元每股。这家号称全球首创稻米造血技术的 生物医药 企业，从资本市场拿到了近26亿元的募资总额，风光无限。 然而，在这光鲜亮丽的资本市场首秀背后，却隐藏着一个关乎企业生存命脉的监管疑问——禾元生物大规模种植转基因水稻，到底要不要农业部 的转基因安全证书？ 01 招股书与农业部各执一词 在禾元生物的多份招股书中，公司一直坚持一个观点：其药用工业用转基因水稻不属于传统农业转基因生物，因此产业化种植无需农业部安全证 书。 禾元生物认为，由于最终产品是药品而非食品或 饲料 ，不会进入食物链，应适用特殊监管路径。 然而，农业农村部科学技术司 生物安全 处工作人员却在2025年7月31日明确表示，禾元生物需取得安全证书，才能产业化 ...

Group 1 - Tianyu Biological reported a revenue of approximately 536 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 14.23% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 1.61 million yuan [1] - As of the report date, Tianyu Biological's market capitalization was 2.6 billion yuan [2] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2] - The technology sector is leading the market's transformation [2]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, with a revenue of 1.148 billion and a net profit of 111 million, reflecting year-on-year growth of 10.54% and 547.7% respectively [1] - In Q3 alone, the company achieved a revenue of 447 million, marking a substantial year-on-year increase of 60.65% and a quarter-on-quarter increase of 28.9% [1] - The company is focusing on research and development innovation, with multiple breakthroughs in its core pipeline and enhanced R&D efficiency through diverse collaborations [1] Group 1: R&D and Product Development - The company has made progress in the oncology field with the GB18 project, a GDF-15 targeted monoclonal antibody, which has entered clinical phase I after receiving approvals from both the FDA and NMPA [1] - Another innovative drug, GB10, aimed at treating retinal neovascular diseases, has had its clinical trial application accepted by the NMPA [1] - The company is expanding its pipeline in the immunology field, targeting large patient populations with conditions such as atopic dermatitis and inflammatory bowel disease [2] Group 2: Strategic Collaborations and Internationalization - The company is actively collaborating with renowned domestic and international institutions, enhancing its R&D efforts on a global scale [3] - It has established a joint initiative for the overseas expansion of the pharmaceutical and medical device industry, providing comprehensive services for international market entry [3] - The company has signed multiple overseas commercialization agreements focusing on major disease areas such as oncology, immunology, orthopedics, and ophthalmology, securing international market collaboration rights for several key products [3]

(本文来自第一财经) 智飞生物公告，2025年第三季度营业收入为27.05亿元，同比下降40.26%；归属于上市公司股东的净利 润亏损6.01亿元。前三季度实现营业收入76.27亿元，同比下降66.53%；归属于上市公司股东的净利润 亏损12.06亿元。 ...

Fulcrum Therapeutics (NasdaqGM:FULC) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsAlan Musso - CFOIain Fraser - SVP of Clinical DevelopmentAlex Sapir - CEO and PresidentMatthew Biegler - Managing DirectorTazeen Ahmad - Managing DirectorConference Call ParticipantsCorinne Johnson - Equity Research AnalystAndres Maldonado - Senior Biotechology AnalystKristen Kluska - Equity Research AnalystEdward Tenthoff - Biotech Equity Research AnalystJoseph P. Schwartz - Senior Research AnalystLu ...

Core Viewpoint - Toxin Pharmaceutical (301089) announced the establishment of a wholly-owned subsidiary, Toxin Pharmaceutical (Inner Mongolia) Co., Ltd., to leverage local energy advantages for optimizing cost structure and enhancing overall development strategy [1] Group 1: Company Strategy - The subsidiary will be registered in Hohhot, Inner Mongolia, with a registered capital of 50 million yuan, focusing on the research, production, and sales of fermentation-related products [1] - The company has a mature microbial fermentation technology platform and extensive experience in traditional mutagenesis and molecular breeding, which supports its operational capabilities [1] Group 2: Market and Economic Context - Inner Mongolia is recognized as a key energy supply base in China, with abundant wind, solar, and thermal power resources, providing significant energy endowment advantages [1] - The low electricity prices in Inner Mongolia are expected to effectively reduce energy costs, which are critical to the company's core competitiveness due to the high energy consumption characteristics of the fermentation process [1]

Core Viewpoint - Tianyu Bio reported a significant decline in revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its business operations [1] Financial Performance - The company's revenue for the third quarter was 123 million yuan, a year-on-year decrease of 38.69% [1] - The net profit for the third quarter showed a loss of 12.43 million yuan, representing a decline of 7,912.82% [1] - For the first three quarters, the total revenue was 536 million yuan, down 14.23% year-on-year [1] - The net profit for the first three quarters was a loss of 1.61 million yuan, which is a decline of 152.22% [1]